Table 1 CSF biomarkers to distinguish cases with ADD from cases with non-ADD

Shoji et al. [12]

55

68

34

Aβ₄₂

158.6 fmol/mL

–

–

–

–

Aβ_42/40 ratio^##

0.078^##

51

82

–

NP

Lewczuk et al. [13]

22

11

35

Aβ₄₂

550 pg/mL

100

80

0.923

–

Aβ_42/40 ratio

9.75

95.2

88.4

0.944

NP

Spies et al. [22]

69

69

47

16 DLB

Aβ₄₂

–

93

87

0.949

–

27 FTD

Aβ_42/40 ratio

–

93

87

0.947

NP

26 VaD

Aβ₄₂

–

83

74

0.811

NP

Aβ_42/40 ratio

–

85

85

0.903

Hertze et al. [32]

94

166 (MCI)

29 (DD)

38

Aβ_{42 MSD}

< 523

73

89

0.88 (0.82–0.93)

–

Aβ_{42 MSD}/₄₀ ratio

< 0.069

93

86

0.91 (0.86–0.95)

NP

Aβ_{42 MSD}/₃₈ ratio

< 0.37

87

82

0.89 (0.83–0.93)

NP

Aβ_{42 MSD}

< 523

67

71

0.73 (0.66–0.80)

–

Aβ_{42 MSD}/₄₀ ratio

< 0.069

85

71

0.86 (0.79–0.91)

NP

Aβ_{42 MSD}/₃₈ ratio

< 0.37

88

71

0.85 (0.79–0.91)

NP

Gabelle et al. [14]

52

34

42

Aβ₄₂

> 464

79

62

0.75

–

Aβ_42/40 ratio

≤11.1

79

76

0.85

n.s.

Aβ₄₂/₃₈ ratio

≤2.00

88

86

0.87

n.s.

Slaets et al. [16]

80

69 (NP)

11 (AD+CVD)

75

24 DLB (15 NP)

29 FTD (12 NP)

22 VaD (11 NP)

30

Aβ₄₂

517 pg/mL

81

59

0.747 (0.670–0.827)

–

Aβ_42/40 ratio

0.057

81

60

0.749 (0.673–0.826)

NP

Nutu et al. [17]

48

127

43 PD

33 PDD

51 DLB

107

Aβ₄₂

444 ng/L

94

72

0.871 (0.811–0.930)

-NP

Aβ_42/40 ratio

0.125

92

79

0.871 (0.801–0.933)

Aβ₄₂

449 ng/L

94

61

0.805 (0.704–0.905)

–

Aβ₄₂/₄₀ ratio

0.150

90

81

0.910 (0.844–0.976)

NP

Aβ₄₂

387 ng/L

88

41

0.675 (0.570–0.780)

–

Aβ_42/40 ratio

0.115

90

57

0.759 (0.664–0.853)

NP

Baldeiras et al. [18]

Aβ₄₂

534 pg/mL

82

74

0.818

–

Aβ_40/42 ratio

8.3

59

81

0.719

NP

AD vs FTD

Aβ₄₂

538 pg/mL

70

82

0.791

–

Aβ_40/42 ratio

5.4

59

87

0.778

NP

Dumurgier et al. [19]

367 (AD+ non-AD)

–

0

Aβ₄₂

737–836 pg/mL

78

79

0.81

–

Aβ_42/40 ratio

0.050–0.082

73

78

0.81

NP

Struyfs et al. [23]

100

50

50

50 (AD)

17 (DLB)

Aβ₄₂

< 722 pg/mL

98.0

74.0

0.874

–

50 (MCI-AD)

17 (FTD)

Aβ_42/40 ratio

< 0.1099

85.7

78.0

0.881

NP

16 (VaD)

Aβ_42/38 ratio

< 0.269

81.6

82.0

0.858

NP

Aβ₄₂

< 694 pg/mL

95.9

40.0

0.686

–

Aβ_42/40 ratio

< 0.1215

93.9

50.0

0.782

NP

Aβ_42/38 ratio

< 0.2730

81.6

68.0

0.804

NP

Bousiges et al. [25]

70

55

15

31 (AD-d)

20 (DLB-d)

Aβ₄₂

≤ 730 ng/L

84.6

71.4

0.84 (0.74–0.92)

–

39 (pro-AD)

35 (pro-DLB)

Aβ_42/40 ratio

≤ 0.0529

88.9

100

0.95 (0.83–0.99)

NP

Aβ₄₂

≤ 504 ng/L

67.7

80

0.77 (0.63–0.88)

–

Aβ_42/40 ratio

≤ 0.0799

92.3

88.9

0.86 (0.64–0.97)

NP

Janelidze et al. [24]

Cohort 2

Cohort 2

Cohort 2

75 (AD)

62 (MCI)

53

Aβ₄₂

–

–

–

0.817 (0.743–0.890)

–

35 (MCI-AD)

34 (VaD)

Cohort 3

Aβ_42/40 ratio

–

–

–

0.879 (0.823–0.936)

< 0.028

Cohort 3

47 (DLB/PDD)

328

Aβ_42/38 ratio

–

–

–

0.856 (0.790–0.923)

< 0.222

137

33 (FTD)

Cohort 3

Aβ₄₂

–

–

–

0.583 (0.476–0.690)

–

35 (DLB/PDD)

Aβ_42/40 ratio

–

–

–

0.792 (0.707–0.877)

< 0.001

128 (PD)

Aβ_42/38 ratio

–

–

–

0.796 (0.710–0.883)

< 0.001

Aβ₄₂

–

–

–

0.698 (0.580–0.816)

–

Aβ_42/40 ratio

–

–

–

0.880 (0.814–0.946)

< 0.001

Aβ_42/38 ratio

–

–

–

0.860 (0.786–0.935)

< 0.001

Aβ₄₂

–

–

–

0.720 (0.651–0.788)

–

Aβ_42/40 ratio

–

–

–

0.863 (0.813–0.912)

< 0.001

Aβ_42/38 ratio

–

–

–

0.863 (0.813–0.913)

< 0.001

Lehmann et al. [26]

342

562

0

Cohort 1

Cohort 1

124

276

Aβ₄₂

500 pg/mL

–

–

0.78 (0.734–0.818)

–

Cohort 2

Cohort 2

Aβ_42/40 ratio

0.1

–

–

0.90 (0.865–0.926)

< 0.0001

218

286

Aβ₄₂

700 pg/mL

–

–

0.60 (0.553–0.641)

–

Aβ_42/40 ratio

0.05

–

–

0.77 (0.728–0.803)

< 0.0001